EXPLORER-HCM
2020
Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
In 251 patients with symptomatic obstructive HCM (NYHA II-III, LVOT gradient ≥50 mmHg), mavacamten improved the composite of peak VO2 and NYHA functional class compared with placebo.
Result
- Absolute difference
- 20 points
- NNT
- 5
difference19.495% CI 8.7-30.1 · P = 0.0005
Absolute difference and NNT are derived from the event rates.
Also reported: LVOT gradient and symptoms also improved.
- Subtopic
- myosin inhibitor
- Design
- Double-blind placebo-controlled RCT, phase 3
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2023 CMPAHA/ACC 2024 HCM
- Source
- Olivotto I, et al. Lancet. 2020;396(10253):759-769.doi 10.1016/S0140-6736(20)31792-X
Discussion & critique
Surrogate/functional composite endpoint rather than hard outcomes, with a modest absolute responder difference. First pivotal trial of a cardiac myosin inhibitor, leading to FDA approval of mavacamten for obstructive HCM.